AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2727638 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (potent acid inhibitor) pretreatment
Number of subjects: 8
Study 796645 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (1500 mg/day)
Number of subjects: 0
Study 796645 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (1200 mg/day)
Number of subjects: 0
Study 31229207 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus nurse-led survivorship model of care (3 face-to-face appointments, tailored resources, SCPTS)
Number of subjects: 60
Study 31229207 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 60
Study 28720233 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology (20 min, twice a week for 24 sessions)
Number of subjects: 45
Study 28720233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 26377190 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle program
Number of subjects: 649
Study 23619129 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure (BP) treatment in treated patients (n=16)
Number of subjects: 20
Study 23619129 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure (BP) treatment
Number of subjects: 20
Study 21411612 — intervention group
Group type: EXPERIMENTAL
Intervention: CasMag-stabilized emulsion containing 30% solid fat
Number of subjects: 20
Study 21411612 — intervention group
Group type: COMPARATOR
Intervention: Control (egg lecithin)
Number of subjects: 20
Study 21411612 — intervention group
Group type: EXPERIMENTAL
Intervention: (13)C-labeled mixed TG in CasMag emulsion
Number of subjects: 20
Study 19667978 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 93
Study 19667978 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 93
Study 17944981 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times a week for 4 weeks
Number of subjects: 17
Study 17944981 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 17
Study 16331761 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg PVAC
Number of subjects: 18
Study 16331761 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg PVAC
Number of subjects: 18
Study 16331761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11782059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical generalized linear models
Number of subjects: 0
Study 9616526 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prednisolone for 3 weeks
Number of subjects: 20
Study 9616526 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 20
Study 8131334 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ankle movement and weight bearing in an orthosis
Number of subjects: 53
Study 8131334 — intervention group
Group type: COMPARATOR
Intervention: No ankle movement but weight bearing in a walking cast
Number of subjects: 53
Study 2683851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30
Study 2683851 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 30
Study 2683851 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study 31802716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thyroxine (T4) infusion for 8 hours
Number of subjects: 28
Study 31802716 — intervention group
Group type: COMPARATOR
Intervention: No T4 infusion (control)
Number of subjects: 28
Study 31802716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thyroxine (T4) infusion for 8 hours (in donors with a history of drug use)
Number of subjects: 28
Study 31802716 — intervention group
Group type: COMPARATOR
Intervention: No T4 infusion (control) (in donors without a history of drug use)
Number of subjects: 28
Study 31294768 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification with intraocular lens implantation (PEI) alone
Number of subjects: 78
Study 31294768 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with intraocular lens implantation and goniosynechialysis (PEI-GSL)
Number of subjects: 78
Study 27624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin/clofarabine (DClo)
Number of subjects: 806
Study 27624670 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin/ara-C (DA)
Number of subjects: 806
Study 27624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine 20 mg/m2 for 5 days with daunorubicin
Number of subjects: 806
Study 27624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of relapse
Number of subjects: 806
Study 27624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival from relapse
Number of subjects: 806
Study 27624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-free survival
Number of subjects: 806
Study 27624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 806
Study 25216939 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser preconditioning (Er,Cr:YSGG laser)
Number of subjects: 6
Study 25216939 — intervention group
Group type: COMPARATOR
Intervention: Sham laser (negative control)
Number of subjects: 6
Study 25216939 — intervention group
Group type: COMPARATOR
Intervention: Composite curing light (positive control)
Number of subjects: 6
Study 23701921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (3 UMCs)
Number of subjects: 6
Study 23701921 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 UMCs)
Number of subjects: 6
Study 23701921 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication materials (posters)
Number of subjects: 6
Study 19756376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combination therapy
Number of subjects: 2860
Study 19615130 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-volume hemofiltration (HVHF) at 6 L/h for 24 hours
Number of subjects: 41
Study 19615130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HVHF treatment)
Number of subjects: 41
Study 15614149 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir or oral ganciclovir prophylaxis for 100 days
Number of subjects: 0
Study 10427657 — intervention group
Group type: EXPERIMENTAL
Intervention: Remicade (Infliximab)
Number of subjects: 0
Study 10427657 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 10427657 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 8561997 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month program of educational videos, small group discussions, pictorial educational materials, and free condom distribution
Number of subjects: 334
Study 8561997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 334
Study 2312776 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK 50 mg
Number of subjects: 12
Study 2312776 — intervention group
Group type: COMPARATOR
Intervention: conventional metoprolol 50 mg tablets
Number of subjects: 12
Study 6903108 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1% + Guanethidine 5%
Number of subjects: 3
Study 6903108 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5% + Guanethidine 3%
Number of subjects: 3
Study 6903108 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 0.2% + Guanethidine 1%
Number of subjects: 3
Study 6903108 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 3
Study 6903108 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 3
Study 31184958 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week progression-based balance-training program
Number of subjects: 15
Study 28327116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, interactive online safety and health intervention (iCAN Plan 4 Safety)
Number of subjects: 450
Study 28327116 — intervention group
Group type: COMPARATOR
Intervention: General online safety information (usual care)
Number of subjects: 450
Study 26408865 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 9
Study 26408865 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 9
Study 23406320 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intradermal (ID) vaccine
Number of subjects: 212
Study 23406320 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intramuscular (IM) vaccine
Number of subjects: 212
Study 23406320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 212
Study 20071637 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 116
Study 20071637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 20071637 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (open-label trial)
Number of subjects: 116
Study 19822836 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus cognitive behavioral skills training telephone intervention
Number of subjects: 2151
Study 17628319 — intervention group
Group type: EXPERIMENTAL
Intervention: ERC 2005 guidelines
Number of subjects: 34
Study 17628319 — intervention group
Group type: COMPARATOR
Intervention: ERC 2000 guidelines
Number of subjects: 34
Study 15128912 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 83
Study 15128912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 15128912 — intervention group
Group type: COMPARATOR
Intervention: NAC or placebo
Number of subjects: 83
Study 11824485 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 122
Study 9509949 — intervention group
Group type: COMPARATOR
Intervention: Total antioxidant status in mild pre-eclampsia
Number of subjects: 75
Study 9509949 — intervention group
Group type: COMPARATOR
Intervention: Total antioxidant status in severe pre-eclampsia
Number of subjects: 75
Study 9509949 — intervention group
Group type: COMPARATOR
Intervention: Total antioxidant status in eclampsia
Number of subjects: 75
Study 7995187 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide treatment
Number of subjects: 30
Study 7995187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29925419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Kind home-visiting program
Number of subjects: 755
Study 29925419 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 755
Study 26633243 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered taste test using 'Taste Strips' (mean score 12.3 ± 2.6)
Number of subjects: 65
Study 26633243 — intervention group
Group type: COMPARATOR
Intervention: Examiner-administered taste test using 'Taste Strips' (mean score 11.6 ± 2.6)
Number of subjects: 65
Study 24146170 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly with calcium and vitamin D supplementation
Number of subjects: 131
Study 24146170 — intervention group
Group type: COMPARATOR
Intervention: Placebo with calcium and vitamin D supplementation
Number of subjects: 131
Study 23343671 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Blend (PB) - ∼19 g
Number of subjects: 19
Study 23343671 — intervention group
Group type: COMPARATOR
Intervention: Whey Protein (WP) - ∼18 g
Number of subjects: 19
Study 21348207 — intervention group
Group type: EXPERIMENTAL
Intervention: kidney‐tonifying and dampness‐expelling Chinese herbal decoction combined with doxazosin
Number of subjects: 64
Study 21348207 — intervention group
Group type: COMPARATOR
Intervention: doxazosin only
Number of subjects: 64
Study 19840533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 67
Study 19840533 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 67
Study 19840533 — intervention group
Group type: COMPARATOR
Intervention: Both bisoprolol and perindopril
Number of subjects: 67
Study 16717293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (initial dose 400 mg/m2, subsequent weekly doses 250 mg/m2) in combination with cisplatin (100 mg/m2) and fluorouracil (FU) (escalating doses of 600, 800, and 1,000 mg/m2/d)
Number of subjects: 53
Study 16717293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (initial dose 400 mg/m2, subsequent weekly doses 250 mg/m2) in combination with carboplatin (AUC 5) and fluorouracil (FU) (escalating doses of 600, 800, and 1,000 mg/m2/d)
Number of subjects: 53
Study 16717293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (cetuximab, cisplatin/carboplatin, and FU)
Number of subjects: 53
Study 15572537 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 511
Study 15572537 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 511
Study 11737876 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation administered with an air-conditioned sunbed, cumulative UVA dose: 96 J/cm2, two exposures weekly for three weeks
Number of subjects: 24
Study 11737876 — intervention group
Group type: COMPARATOR
Intervention: No UVA exposures (Control group)
Number of subjects: 24
Study 9240635 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-Neon laser treatment (632.8 nm wavelength, power 60 mW), applied daily from d-5 to d-1 on five anatomic sites of the oral mucosa.
Number of subjects: 30
Study 8260235 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with BCNU 80 mg/m2 i.v. every 4 weeks, actinomycin-D 10 micrograms/kg, vincristine 1.0 mg/m2 i.v. every 2 weeks for 6 months
Number of subjects: 173
Study 8260235 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 173
Study 3653755 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal distension during fasting
Number of subjects: 6
Study 3653755 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal distension postprandially
Number of subjects: 6
Study 31668839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus oxaliplatin (GEMOX) - gemcitabine 1000 mg/m2, oxaliplatin 100 mg/m2 on day 1 every 2 weeks
Number of subjects: 80
Study 31668839 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GCb) - gemcitabine 1000 mg/m2 on day 1 and day 8, carboplatin AUC 4.5 mg/mL/min on day 1 every 3 weeks
Number of subjects: 80
Study 29902447 — intervention group
Group type: EXPERIMENTAL
Intervention: Belladonna and opiate suppository (16.2/7.5 mg)
Number of subjects: 26
Study 29902447 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 26
Study 27067068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (N = 88), administered in five weekly 90-min sessions.
Number of subjects: 170
Study 27067068 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (N = 82).
Number of subjects: 170
Study 27067068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (N = 88).
Number of subjects: 170
Study 25118119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive management
Number of subjects: 1051
Study 25118119 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1051
Study 23680352 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe diarrhoea
Number of subjects: 9439
Study 23680352 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-ETEC
Number of subjects: 9439
Study 23680352 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical enteropathogenic E. coli
Number of subjects: 9439
Study 23680352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptosporidium
Number of subjects: 9439
Study 23680352 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without diarrhoea)
Number of subjects: 9439
Study 19933915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin
Number of subjects: 482
Study 19933915 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study 18423274 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed document of informed consent disclosing possible risks
Number of subjects: 60
Study 18423274 — intervention group
Group type: COMPARATOR
Intervention: Simplified version of informed consent
Number of subjects: 60
Study 15722903 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation correction using Hawkeye low‐resolution X‐ray computed tomography
Number of subjects: 94
Study 15722903 — intervention group
Group type: COMPARATOR
Intervention: Non-corrected images
Number of subjects: 94
Study 15722903 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation correction
Number of subjects: 94
Study 14514531 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 38
Study 14514531 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioception training (P)
Number of subjects: 38
Study 14514531 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength + proprioception training (B)
Number of subjects: 38
Study 14514531 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 38
Study 10534248 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 U of BoNT/B
Number of subjects: 109
Study 10534248 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 U of BoNT/B
Number of subjects: 109
Study 10534248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 10534248 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/B (both doses)
Number of subjects: 109
Study 8550773 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1-(7-36) amide (1.2 pmol/kg.min)
Number of subjects: 8
Study 8550773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl with 1% human serum albumin)
Number of subjects: 8
Study 2065808 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hCG/oocyte retrieval interval (34 hours) with immediate insemination
Number of subjects: 60
Study 2065808 — intervention group
Group type: EXPERIMENTAL
Intervention: Long hCG/oocyte retrieval interval (39 hours) with immediate insemination
Number of subjects: 60
Study 2065808 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hCG/oocyte retrieval interval (34 hours) with delayed insemination (after 5 hours)
Number of subjects: 60
Study 2065808 — intervention group
Group type: EXPERIMENTAL
Intervention: Long hCG/oocyte retrieval interval (39 hours) with delayed insemination (after 5 hours)
Number of subjects: 60
Study 2065808 — intervention group
Group type: COMPARATOR
Intervention: Preincubation before insemination
Number of subjects: 60
Study 7092498 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of DE gamma E intramuscularly (IM) daily for ten days
Number of subjects: 23
Study 7092498 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of DE gamma E intramuscularly (IM) daily for ten days
Number of subjects: 23
Study 7092498 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of DE gamma E IM daily for ten days
Number of subjects: 23
Study 7092498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30914185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia mobile application
Number of subjects: 110
Study 30914185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study 28965346 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic condition (HYPO; FiO2, 14.5%)
Number of subjects: 19
Study 28965346 — intervention group
Group type: COMPARATOR
Intervention: Normoxic condition (NOR; FiO2, 20.9%)
Number of subjects: 19
Study 28965346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 27091951 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Triple P training
Number of subjects: 81
Study 27091951 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 81
Study 25229168 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg once a day)
Number of subjects: 20
Study 25229168 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg once a day)
Number of subjects: 20
Study 23011378 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg/day for 3 months) with topical corticosteroid treatment
Number of subjects: 112
Study 19605972 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line drugs (benzodiazepines: lorazepam, diazepam)
Number of subjects: 0
Study 19605972 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line drugs (phenytoin, fosphenytoin)
Number of subjects: 0
Study 19605972 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory status epilepticus treatments (barbiturates: phenobarbital, pentobarbital, thiopental; valproate; midazolam; propofol; isoflurane)
Number of subjects: 0
Study 19605972 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized convulsive status epilepticus
Number of subjects: 0
Study 17477769 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's recommendation for testing
Number of subjects: 533
Study 14994883 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear (HG) treatment for 16 months
Number of subjects: 68
Study 14994883 — intervention group
Group type: COMPARATOR
Intervention: Control group with only interceptive procedures
Number of subjects: 68
Study 11352393 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel (Ametop)
Number of subjects: 20
Study 11352393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% eutectic mixture of lidocaine and prilocaine (EMLA)
Number of subjects: 20
Study 11352393 — intervention group
Group type: COMPARATOR
Intervention: E45 cream (placebo)
Number of subjects: 20
Study 11352393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8204495 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 80 micrograms/kg
Number of subjects: 0
Study 8204495 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 80 micrograms/kg plus butorphanol 40 micrograms/kg
Number of subjects: 0
Study 3445800 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova T (NTCu200Ag) IUD
Number of subjects: 800
Study 3445800 — intervention group
Group type: COMPARATOR
Intervention: Multiload 250 (MLCu250) IUD
Number of subjects: 800
Study 31094331 — intervention group
Group type: COMPARATOR
Intervention: Guided i-RFCBT
Number of subjects: 235